-

MedX Announces Appointment of Stephen Lockyer as CEO

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Stephen Lockyer has been appointed as Chief Executive Officer, effective immediately, in place of Naman Damaghlatrous, who has resigned both as an officer and director of the Company.

“Stephen, who became a major investor in the company in recent months, and who joined the Board in April, 2023, brings extensive knowledge and years of financial management and entrepreneurial experience, and was instrumental in the introduction of the project with PharmaChoice which has just been launched in Canada,” said Ken McKay, Chairman of the MedX Board of Directors.

Mr. Lockyer stated, “I am very enthusiastic for the future of MedX, and I look forward to building on the opportunities that are now opening up.”

About MedX Health Corp.:

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547

MedX Health Corp.

TSX VENTURE:MDX

Release Summary
MEDX ANNOUNCES APPOINTMENT OF STEPHEN LOCKYER AS CEO
Release Versions

Contacts

Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547

More News From MedX Health Corp.

MedX announces proposed Non-Brokered Private Placement to raise up to $2,500,000 and Stock Option Grants

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing to raise up to $2,500,000 by way of a Non-Brokered Private Placement of up to 35,714,858 Units at $0.07 per Unit (“Unit”). Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (“Warrant(s)”), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on th...

MedX Announces Application for Extension for a further $300,000 of Series I Loan Notes

MISSISSAUGA, Ontario--(BUSINESS WIRE)--In its Press Release dated October 22, 2024, MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it had obtained final TSXV Acceptance for extension of the Maturity Date of $2,650,000 out of $3,700,000 of then outstanding Convertible Loan Notes (“Series I Notes”) from December 31, 2023 to December 31, 2025 (the “Extension”), and that it may submit request(s) to the TSXV for Acceptance in the event that additional holders of Series I Not...

MedX Health Corp. announces Amended Application for Series I Loan Note Extension

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that further to its Press Release dated August 6, 2024, the TSXV issued a Final Acceptance Letter dated August 14, 2024, in respect of the Amendment to the remaining outstanding $3,700,000 of the Series I Loan Notes issued in 2021, by the Extension of the Maturity Date from December 31, 2023, to December 31, 2025, but has since withdrawn that Final Acceptance. The Company is now filing an a...
Back to Newsroom